Evidence map›Paper›PMID 34269919›Full record

ReviewCurrent oncology reports2021

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?

Claudio Luchini, Rita T Lawlor, Samantha Bersani, Caterina Vicentini, Gaetano Paolino, Paola Mattiolo, Antonio Pea, Sara Cingarlini, Michele Milella, Aldo Scarpa

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, 37134, Verona, Italy.
Rita T LawlorARC-Net Research Centre, University and Hospital Trust of Verona, 37134, Verona, Italy.
Samantha BersaniARC-Net Research Centre, University and Hospital Trust of Verona, 37134, Verona, Italy.
Caterina VicentiniARC-Net Research Centre, University and Hospital Trust of Verona, 37134, Verona, Italy.
Gaetano PaolinoARC-Net Research Centre, University and Hospital Trust of Verona, 37134, Verona, Italy.
Paola MattioloDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, 37134, Verona, Italy.
Antonio PeaDepartment of Surgery, University and Hospital Trust of Verona, Verona, Italy.
Sara CingarliniDepartment of Medicine, Section of Oncology, University and Hospital Trust of Verona, Verona, Italy.
Michele MilellaDepartment of Medicine, Section of Oncology, University and Hospital Trust of Verona, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, 37134, Verona, Italy. aldo.scarpa@univr.it.ORCID 0000-0003-1678-739X
University of Verona · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 12182Fondazione Cariverona 203885/2017Fondazione italiana Malattie Pancreas J38D19000690001
6 · The paper itself

Abstract

purpose of reviewAlternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by some types of malignancies, including pancreatic neuroendocrine tumors, to overcome the issue of telomere shortening, thus supporting tumor growth and cell proliferation. This review is focused on the most important achievements and opportunities deriving from ALT assessment in PanNET onco-pathology, highlighting the most promising fields in which such biomarker could be implemented in clinical practice. RECENT

findingsIn pancreatic neuroendocrine tumors (PanNET), ALT is strongly correlated with the mutational status of two chromatin remodeling genes, DAXX and ATRX. Recent advances in tumor biology permitted to uncover important roles of ALT in the landscape of PanNET, potentially relevant for introducing this biomarker into clinical practice. Indeed, ALT emerged as a reliable indicator of worse prognosis for PanNET, helping in clinical stratification and identification of "high-risk" patients. Furthermore, it is a very specific marker supporting the pancreatic origin of neuroendocrine neoplasms and can be used for improving the diagnostic workflow of patients presenting with neuroendocrine metastasis from unknown primary. The activation of this process can be determined by specific FISH analysis. ALT should be introduced in clinical practice for identifying "high-risk" PanNET patients and improving their clinical management, and as a marker of pancreatic origin among neuroendocrine tumors.

Indexed as

MutationTelomere HomeostasisBiomarkers, TumorCo-Repressor ProteinsGenetic Predisposition to DiseaseHumansIn Situ Hybridization, FluorescenceMolecular ChaperonesNeuroendocrine TumorsPancreatic NeoplasmsTelomereX-linked Nuclear ProteinATRX protein, humanBiomarkers, TumorCo-Repressor ProteinsDAXX protein, humanMolecular ChaperonesX-linked Nuclear ProteinALTATRXDAXXPancreatic neuroendocrine tumorsPanNET

Identifiers

PMID34269919
PMCPMC8285324
OpenAlexW3177576647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.